The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of TMB estimates for the prediction of response to immune checkpoint blockage.
 
Jan Budczies
No Relationships to Disclose
 
Michael Allgäuer
No Relationships to Disclose
 
Kevin Litchfield
Patents, Royalties, Other Intellectual Property - Patent on indel burden and checkpoint inhibitor response pending
 
Eugen Rempel
No Relationships to Disclose
 
Petros Christopoulos
No Relationships to Disclose
 
Daniel Kazdal
No Relationships to Disclose
 
Volker Endris
Honoraria - AstraZeneca; Thermo Fisher Scientific
Consulting or Advisory Role - Novartis/Pfizer
 
Michael Thomas
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; IQvia; IQvia; Lilly; Mediolanum Farmaceutici; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Stefan Fröhling
No Relationships to Disclose
 
Solange Peters
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; Merck Serono; MSD; Novartis; Pfizer; Regeneron; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Charles Swanton
Stock and Other Ownership Interests - Achilles Therapeutics; Apogen Biotechnologies; Epic Sciences; GRAIL
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Illumina; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Roche; SERVIER
Consulting or Advisory Role - Genentech/Roche; Sarah Cannon Research Institute
Research Funding - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Founder of Achilles Therapeutics: a biotechnology company funded by Syncona/Wellcome Trust to target clonal Neoantigens through vaccine and cell therapy approaches; Patent WO2016174085 A1: Method for treating cancer based on identification of clonal neo-antigens; Patent WO2017042394 A1 :Methods for identifying a subject with cancer who is suitable for treatment with an immune checkpoint intervention
 
Peter Schirmacher
Honoraria - AstraZeneca; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
 
Albrecht Stenzinger
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; Novartis; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Illumina; MSD; Novartis; Roche; Thermo Fisher Scientific
Research Funding - Bristol-Myers Squibb; Chugai Pharma